Literature DB >> 12123345

Gastrointestinal toxicity associated with weekly docetaxel treatment.

H J Stemmler1, S Kenngotte, H Diepolder, V Heinemann.   

Abstract

Previous studies have demonstrated a marked reduction of haematological and non-haematological toxicity if weekly doses of docetaxel <40 mg/m2 were used. Reviewing the literature, neutropenic enterocolitis is uncommon but not unknown in patients treated with taxane-based chemotherapy. Although this complication occurs rarely, here we report on two patients, one with metastatic breast cancer and one with non-small-cell lung cancer, treated on a weekly schedule with single-agent docetaxel. Both patients developed excessive and fatal haemorrhragic gastroduodenitis and enterocolitis associated with grade 2 and 3 neutropenia. We would like to stress the importance of symptoms such as abdominal pain and tenderness, fever, diarrhoea and mucositis, with or without neutropenic fever, in patients treated with docetaxel-based chemotherapy. These symptoms should alert the physician and supportive care management should be started aggressively and immediately.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123345     DOI: 10.1093/annonc/mdf084

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

Review 1.  Systematic review of case reports concerning adults suffering from neutropenic enterocolitis.

Authors:  Andrés Felipe Cardona Zorrilla; Ludovic Reveiz Herault; Alexandra Casasbuenas; Diego Mauricio Aponte; Pedro Luis Ramos
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  Neutropenia and enterocolitis with docetaxel treatment.

Authors:  Alberto Ocaña Fernández; Ignacio Martín González; Amalia Gómez Bernal; Juan Jesús Cruz Hernández
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

Review 3.  Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.

Authors:  CelesteAnn T Bremer; Brian P Monahan
Journal:  Curr Gastroenterol Rep       Date:  2006-08

4.  Collateral damage: taxane-induced colonic perforation.

Authors:  Jennifer Erdrich; Zachary J Kastenberg; Michael A DiMaio; Teri A Longacre; Kim F Rhoads
Journal:  Dig Dis Sci       Date:  2015-02       Impact factor: 3.199

5.  The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.

Authors:  Rupert Bartsch; Guenther G Steger
Journal:  Breast Care (Basel)       Date:  2009-06-23       Impact factor: 2.860

6.  No relation between docetaxel administration route and high-grade diarrhea incidence.

Authors:  Jeroen J M A Hendrikx; Frederik E Stuurman; Ji-Ying Song; Vincent A de Weger; Jurjen S Lagas; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel; Jan H M Schellens; Serena Marchetti
Journal:  Pharmacol Res Perspect       Date:  2020-08

7.  Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials.

Authors:  Zheng Xiao; Chengqiong Wang; Lianhong Li; Xuemei Tang; Nana Li; Jing Li; Ling Chen; Qihai Gong; Fushan Tang; Jihong Feng; Xiaofei Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-11       Impact factor: 2.629

8.  Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota.

Authors:  Qingya Liu; Yi Lu; Yao Xiao; Liping Yuan; Danrong Hu; Ying Hao; Ruxia Han; Jinrong Peng; Zhiyong Qian
Journal:  Adv Sci (Weinh)       Date:  2021-10-28       Impact factor: 16.806

Review 9.  Neutropenic Enterocolitis and Sepsis: Towards the Definition of a Pathologic Profile.

Authors:  Giuseppe Bertozzi; Aniello Maiese; Giovanna Passaro; Alberto Tosoni; Antonio Mirijello; Stefania De Simone; Benedetta Baldari; Luigi Cipolloni; Raffaele La Russa
Journal:  Medicina (Kaunas)       Date:  2021-06-20       Impact factor: 2.430

10.  Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report.

Authors:  Hee Yeon Lee; Youn Hee Lee; Min Ji Kim; Hoon-Kyo Kim
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.